Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunover for Genitourinary Syndrome of Menopause
NCT05464654Completed
- Sponsor
- Hospital Regional 1° de Octubre
- Start
- Jun 2021
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Randomised, open-label trial of polideoxirybonucleotide in genitourinary syndrome of menopause (GSM), sponsored by Hospital Regional 1° de Octubre. Primary endpoint: Change from baseline urogenital domain score in the Menopause Rating Scale at 3 months. Started Jun 2021; status: completed.
02
Drugs
polideoxirybonucleotide
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT05464654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464654.